[Use of dimethothiazine in the prevention of hemicrania].
The best results in the prevention of migraine have so far been obtained with tricyclic antihistamine, anti-5HT drugs. Experimentation of dimethothiazine--already widely employed in the management of essential headache--in this field is reported. Results obtained in a double-blind trial with a placebo on randomised levels and on a large series evaluated with Pearson's scatter index showed that the drug was effective, especially in the prevention of classic migraine. It was also usuable during attacks and in the prevention of cluster headache. Good tolerance and the absence of side-effects suggest the adoption of a standard course of 60 mg/day for not less than 2 to 3-4 months. Other therapeutic courses may be alternated during the year.
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy / Q000517:prevention & control*; D010640:Phenothiazines / Q000627:therapeutic use*; D014653:Vascular Headaches / Q000188:drug therapy
D010640:Phenothiazines
L'impiego della dimetotiazina nella profilassi dell'emicrania